Ashwin Shahir

2.6k total citations · 1 hit paper
26 papers, 677 citations indexed

About

Ashwin Shahir is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Ashwin Shahir has authored 26 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Ashwin Shahir's work include Advanced Breast Cancer Therapies (10 papers), Vascular Tumors and Angiosarcomas (7 papers) and Sarcoma Diagnosis and Treatment (7 papers). Ashwin Shahir is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), Vascular Tumors and Angiosarcomas (7 papers) and Sarcoma Diagnosis and Treatment (7 papers). Ashwin Shahir collaborates with scholars based in United States, United Kingdom and Spain. Ashwin Shahir's co-authors include Robin L. Jones, William D. Tap, Robert Ilaria, Brian A. Van Tine, Jan Cosaert, Amy Qin, Mark Agulnik, Ilaria Conti, Damien M. Cronier and Michael B. Livingston and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Ashwin Shahir

26 papers receiving 664 citations

Hit Papers

Olaratumab and doxorubicin versus doxorubicin alone for t... 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
    2016 436 citations William D. Tap, Robin L. Jones et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ashwin Shahir United States 11 476 400 172 101 85 26 677
Douglas Adkins United States 8 389 0.8× 360 0.9× 120 0.7× 79 0.8× 89 1.0× 19 659
Amy Qin United States 8 487 1.0× 472 1.2× 130 0.8× 99 1.0× 55 0.6× 12 720
Mary Lou Keohan United States 12 672 1.4× 492 1.2× 275 1.6× 138 1.4× 85 1.0× 22 923
Maria Marples United Kingdom 10 357 0.8× 512 1.3× 104 0.6× 69 0.7× 41 0.5× 31 722
Geraldine Goss Australia 13 494 1.0× 452 1.1× 141 0.8× 153 1.5× 111 1.3× 24 819
Youn Choi Park United States 8 617 1.3× 548 1.4× 199 1.2× 183 1.8× 120 1.4× 13 1.0k
Gregory Pennock United States 3 334 0.7× 277 0.7× 113 0.7× 72 0.7× 36 0.4× 4 441
Zsuzsa Pápai Hungary 9 750 1.6× 566 1.4× 235 1.4× 180 1.8× 79 0.9× 10 908
Kelly Scheu United States 5 359 0.8× 389 1.0× 80 0.5× 91 0.9× 43 0.5× 10 723
Marie‐Pierre Sunyach France 15 541 1.1× 299 0.7× 103 0.6× 120 1.2× 68 0.8× 58 858

Countries citing papers authored by Ashwin Shahir

Since Specialization
Citations

This map shows the geographic impact of Ashwin Shahir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashwin Shahir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashwin Shahir more than expected).

Fields of papers citing papers by Ashwin Shahir

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashwin Shahir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashwin Shahir. The network helps show where Ashwin Shahir may publish in the future.

Co-authorship network of co-authors of Ashwin Shahir

This figure shows the co-authorship network connecting the top 25 collaborators of Ashwin Shahir. A scholar is included among the top collaborators of Ashwin Shahir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashwin Shahir. Ashwin Shahir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goetz, Matthew P., İrfan Çiçin, Laura Testa, et al.. (2024). Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. npj Breast Cancer. 10(1). 34–34. 12 indexed citations
2.
O’Shaughnessy, Joyce, Laura Testa, Sara M. Tolaney, et al.. (2023). 274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study. Annals of Oncology. 34. S293–S293. 1 indexed citations
3.
4.
Grischke, Eva‐Maria, Antonio Llombart‐Cussac, Masakazu Toi, et al.. (2023). Final Overall Survival Analysis of MONARCH 2: A Phase 3 Trial of Abemaciclib plus Fulvestrant in Patients with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 20(2). e5–e6. 1 indexed citations
5.
Llombart‐Cussac, Antonio, George W. Sledge, Masakazu Toi, et al.. (2023). Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Cancer Research. 83(5_Supplement). PD13–11. 11 indexed citations
6.
Mascarenhas, Leo, Chitose Ogawa, Theodore W. Laetsch, et al.. (2021). Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Medicine. 10(3). 843–856. 2 indexed citations
7.
O’Shaughnessy, Joyce, Priya Rastogi, Nadia Harbeck, et al.. (2021). VP8-2021: Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE. Annals of Oncology. 32(12). 1646–1649. 5 indexed citations
8.
Jones, Robin L., Andrew J. Wagner, Akira Kawai, et al.. (2021). Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clinical Cancer Research. 27(14). 3861–3866. 31 indexed citations
9.
Villalobos, Víctor M., Gary Mo, Mark Agulnik, et al.. (2019). Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma. Cancer Medicine. 9(3). 882–893. 2 indexed citations
10.
Jones, Robin L., Dorothea Wagner, Ashwin Shahir, et al.. (2019). Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial. Annals of Oncology. 30. v685–v686. 1 indexed citations
11.
Tine, Brian A. Van, Rangaswamy Govindarajan, Steven Attia, et al.. (2019). Incidence and Management of Olaratumab Infusion-Related Reactions. Journal of Oncology Practice. 15(11). e925–e933. 2 indexed citations
12.
Hakenberg, Oliver W., José Luis Perez‐Gracia, Daniel Castellano, et al.. (2018). Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer. 107. 186–195. 10 indexed citations
13.
14.
Gerber, David E., Paul Swanson, Ariel López-Chávez, et al.. (2017). Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer. 111. 108–115. 9 indexed citations
15.
Goldman, Jonathan W., Lee S. Rosen, Anthony W. Tolcher, et al.. (2017). Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer. Investigational New Drugs. 36(4). 629–637. 13 indexed citations
16.
Tap, William D., Robin L. Jones, Brian A. Van Tine, et al.. (2016). Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. The Lancet. 388(10043). 488–497. 436 indexed citations breakdown →
17.
18.
19.
Abu-Omar, Yasir, et al.. (2011). The impact of off-pump coronary artery bypass surgery on postoperative renal function. Perfusion. 27(2). 127–131. 9 indexed citations
20.
Westaby, Stephen, et al.. (2009). Mechanical bridge to recovery in pheochromocytoma myocarditis. Nature Reviews Cardiology. 6(7). 482–487. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Douglas Adkins Breakdown of academic impact, for papers by Amy Qin Breakdown of academic impact, for papers by Mary Lou Keohan Breakdown of academic impact, for papers by Maria Marples Breakdown of academic impact, for papers by Geraldine Goss Breakdown of academic impact, for papers by Youn Choi Park Breakdown of academic impact, for papers by Gregory Pennock Breakdown of academic impact, for papers by Zsuzsa Pápai Breakdown of academic impact, for papers by Kelly Scheu Breakdown of academic impact, for papers by Marie‐Pierre Sunyach
Rankless by CCL
2026